CagriSema

Q: What is the typical dosage for CagriSema?

The typical dosage is 2.4 mg semaglutide + 2.4 mg cagrilintide weekly, administered via Subcutaneous injection.

Q: What is the half-life of CagriSema?

The half-life of CagriSema is ~7–8 days (each component).

Q: Is CagriSema FDA approved?

No, CagriSema is currently classified as "Clinical Trials" and is not FDA approved for general use.

Also known as: Cagrilintide + Semaglutide

A fixed-ratio combination of cagrilintide and semaglutide achieving 25%+ weight reduction by dual-pathway suppression of hunger centers.

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~7–8 days (each component)

Typical Dose

2.4 mg semaglutide + 2.4 mg cagrilintide weekly

Administration

Subcutaneous injection

Mechanism of Action

Merges GLP-1 agonism with amylin pathway activation for overwhelming, synergistic appetite suppression exceeding either compound alone.

Key Research Areas

weight losscombinationamylinGLP-1

Frequently Asked Questions

What is CagriSema?▾

A fixed-ratio combination of cagrilintide and semaglutide achieving 25%+ weight reduction by dual-pathway suppression of hunger centers.

How does CagriSema work?▾

Merges GLP-1 agonism with amylin pathway activation for overwhelming, synergistic appetite suppression exceeding either compound alone.

What is the recommended dosage for CagriSema?▾

The typical research dosage is 2.4 mg semaglutide + 2.4 mg cagrilintide weekly, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.

What is the half-life of CagriSema?▾

The half-life of CagriSema is approximately ~7–8 days (each component). This affects dosing frequency and timing in research protocols.

Is CagriSema FDA approved?▾

CagriSema is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about CagriSema is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Weight Loss

Semaglutide

Ozempic · Wegovy

Tirzepatide

Mounjaro · Zepbound

Retatrutide

LY3437943 · Triple G agonist

Liraglutide

Victoza · Saxenda

Back to All Peptides Find Your Peptide — Take the Quiz